299 related articles for article (PubMed ID: 31337426)
1. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
[TBL] [Abstract][Full Text] [Related]
2. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
3. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
[TBL] [Abstract][Full Text] [Related]
4. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
5. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
Higashino N; Koma YI; Hosono M; Takase N; Okamoto M; Kodaira H; Nishio M; Shigeoka M; Kakeji Y; Yokozaki H
Lab Invest; 2019 Jun; 99(6):777-792. PubMed ID: 30683902
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer.
Son GM; Kwon MS; Shin DH; Shin N; Ryu D; Kang CD
Medicine (Baltimore); 2019 May; 98(18):e15164. PubMed ID: 31045759
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
Mathieson L; Koppensteiner L; Dorward DA; O'Connor RA; Akram AR
Br J Cancer; 2024 May; 130(11):1758-1769. PubMed ID: 38582812
[TBL] [Abstract][Full Text] [Related]
10. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
[TBL] [Abstract][Full Text] [Related]
11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma.
Ha SY; Yeo SY; Xuan YH; Kim SH
PLoS One; 2014; 9(6):e99955. PubMed ID: 24945657
[TBL] [Abstract][Full Text] [Related]
13. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
15. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin I inhibits gastric cancer cell proliferation by downregulating the expression of fibroblast activation protein alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated fibroblasts.
Dong R; Guo J; Zhang Z; Zhou Y; Hua Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):1129-1134. PubMed ID: 29499193
[TBL] [Abstract][Full Text] [Related]
17. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
18. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.
Cremasco V; Astarita JL; Grauel AL; Keerthivasan S; MacIsaac K; Woodruff MC; Wu M; Spel L; Santoro S; Amoozgar Z; Laszewski T; Migoni SC; Knoblich K; Fletcher AL; LaFleur M; Wucherpfennig KW; Pure E; Dranoff G; Carroll MC; Turley SJ
Cancer Immunol Res; 2018 Dec; 6(12):1472-1485. PubMed ID: 30266714
[TBL] [Abstract][Full Text] [Related]
19. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Sorrentino C; Miele L; Porta A; Pinto A; Morello S
Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
[TBL] [Abstract][Full Text] [Related]
20. Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome.
Mezheyeuski A; Segersten U; Leiss LW; Malmström PU; Hatina J; Östman A; Strell C
Sci Rep; 2020 Jan; 10(1):281. PubMed ID: 31937798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]